Clozapine was first made in 1958 and sold commercially in 1972.[9] It was the first atypical antipsychotic.[10] It is on the WHO Model List of Essential Medicines, which lists the most effective and safe medicines needed in a health system.[11] It is available as a generic medication.[...
headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions (constipation and nausea); and fever. ...
EDITOR,—We have been aware for some time that the strict haematological limits used by the Clozaril Patient Monitoring Service may exclude patients who normally have low white cell counts from receiving clozapine. Lawton et al reported "normal neutropenia" in an Afro-Caribbean patient taking ...
CLOZARIL Treatment And Monitoring In The General Patient Population (see Table 2) Obtain a CBC, including the ANC value, prior to initiating treatment with CLOZARIL to ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/μL) and to permit later comparison...
for a patient to begin treatment with CLOZARIL. During treatment, patients must have regular monitoring of ANC and WBC. Discontinue CLOZARIL and do not rechallenge if the ANC is less than 1000/mm 3 or the WBC is less than 2000/mm ...
(weeklymonitoringininitialsystemandeverytwoweeksincurrentsystem) Source:Appendix1,Post-texttable3.2-1b Differencebetween Systems(with95% CIandpvalue) Agranulocytosis 0.03(-0.21,0.27) (p=0.80) 0.4 0.37 0.0 0.2 0.4 0.6 0.8 1.0 Agranulocytosis ...
Cardiovascular System Atrial or ventricular fibrillation, ventricular tachycardia, palpitations, QT interval prolongation, Torsades de Pointes, mitral valve incompetence associated with clozapine-related cardiomyopathy, myocardial infarction, cardiac arrest, myocarditis, and periorbital edema. ...